Cargando…
Use of Contezolid for the Treatment of Refractory Infective Endocarditis in a Patient with Chronic Renal Failure: Case Report
Infective endocarditis (IE) caused by methicillin-resistant Staphylococcus aureus (MRSA) is usually life threatening and difficult to treat. Contezolid is a newly approved oxazolidinone antimicrobial agent showing potent activity against MRSA. We successfully treated a case of refractory IE caused b...
Autores principales: | Zhao, Sheng, Zhang, Wei, Zhang, Linfei, Zhang, Jing, Li, Jinghang, Si, Linjie, Ding, Yi, Li, Mingke, Song, Yuanyuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10276592/ https://www.ncbi.nlm.nih.gov/pubmed/37333679 http://dx.doi.org/10.2147/IDR.S413452 |
Ejemplares similares
-
Contezolid: First Approval
por: Hoy, Sheridan M.
Publicado: (2021) -
1700. Efficacy and Safety in Subjects with Renal Impairment in Contezolid and Contezolid Acefosamil Phase 2 and Phase 3 Skin Infection Clinical Trials
por: Fang, Edward, et al.
Publicado: (2022) -
1118. Population Pharmacokinetics of Contezolid Acefosamil and Contezolid – Rationale for a Safe and Effective Loading Dose Regimen
por: Bulitta, Jürgen B, et al.
Publicado: (2021) -
Identification key genes, key miRNAs and key transcription factors of lung adenocarcinoma
por: Li, Jinghang, et al.
Publicado: (2020) -
A Novel Oxazolidinone, Contezolid (MRX-I), Expresses Anti-Mycobacterium abscessus Activity In Vitro
por: Guo, Qi, et al.
Publicado: (2021)